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By J.etter of L6 December 1980 the President of the Council of the
European Communlties requ€sted the European Parliament, purauant to
Artiele L00 of the EEc Treaty, to deliver an opinion on the proposals
from the Commission of the European Comrnrnitiea to the Council for a
directive amending Directives 65/65/EEC, 75/3L8/WC and 75/3L9/EEC on the
approximation of provisions lald down by law, regulatlon or adninistrative
actLon relatlng to proprietary medicinal products and for a lecomrendatlon
concernlng teets relating to the placing on the market of proprietary
medicinal products. (Doc. L-787/8O) .
The President of the European Parliament referred these proposals to
the Committee on Economic and Monetary Affairs as the committee responEible
and to the Committee on the Environrnent, Public Health and Consumer
Protection for its oPinion.
On 3O January 1981 the Committee on Economlc and l,lonetary Affairs
appointed Mr von Wogau raPporteur.
It considered these prcposals at its meeting of 13 and 14 !{ay L981.
At its meeting of L4 May 1981, the committee unanimously adopted:
- 
the proposal for a directive amending Directives 65/65/EEC, 75/3L8,/EEC ancl
75/3L9/EEC on proprietary medicinal productE,
- the proposal for a recommendation concerning tests relatlng to the placing
on the market of proprietary rnediclnal products (Doc. L-7A7/8O\ 
'
- the motion for a resol-ution.
Present: !,Ir DEITEAU, acting chairman; !!r DE FERRANII, vice-chairmani
t'lr von WOGAU, rapporteurr Mr ALBERS (deputizing for Mr SCIIWARTZENBERG),
Mr BEAZLEY, !!r DAMSIEAIIX (deputizing for lrlr COMBE), Mr IiIERlllAN, !{r LANGE
(deputizing for Mr DELORS), Mr DIIIIR, Mr PETRONIO, !,1r TITRNER (deputizing
for Mr HoPPER) and I,Ir VB'GNER.
By letter of 30 April 1981, the chairnran of the Committee on the
Environment, Public Health and Consumer Protectlon stated that h.'s cornnitteers
opinion would be delivered separately.
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AThe Committee on Economic and Monetary Affairs hereby submits to
th6 European Parliament the folloring motion for a resolution together
wlth explanatory statenenta
MOTION FOR A RESOIJTITION
embodying thc opinlon of the European ParlLament on the proposal from the
Commlsslon of the European Comrounities to the Councll for a direetlve
amending Directives 65/65/EEC, 75/318/EEC Ed 75/3L9/EEC on the approximation
of provislons lald down by Iaw, regulatlon or adslalEtratlve aetl.on relating
to prbprtetary medicinal products.
rhe_E@,
- having regar:d to the proposal from the commisEion of the European
Communities to the Councill,
- having been consulted by the Council (Doc.1-787 /AO) ,
- having regard to the report. of the Committee on Economic and t'lonatary
Affairs (Doc. I-246/8]-l,
1. Stresses the lmportance of the free movement of medicinal products
both for the protection of public health and the develogrnent and
international competitiveness of the Community' s phar:naceutical
lndustryt
2. Notes that, despite the directives so far adopted, a great number of
technical lrarriers to the free movement of medlcinal products still
remain, partlcularly with regard to the admission of new products to
the markEt; these remaining technical barriere are the results, in part,
of:
- the defec:ts in the present procedure for the placing on the market
of medicinal Products,
- the lack of honogeneity in Irlember States' regulations governing the
informatj.on required for new proprietary medicinal products to be
allovred on the market;
3. Approves, t:herefore, the principle behind the amendments proposed by
the Commlssiion to the marketing procedure, introducing the mutual
recognltiorr of marketing authorizations issued by the Member States
and the harmonization of the tests required to obtain such authorizations;
eonslders t:hat the mututal recognition of marketing authorizatione is
the most appropriate procedure for attaining the free movement of medicinal
products;
I
- OJ No. c 35: of 31.L2.8O, p.t.
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4. considere that the new proeedure shourd make it possible to:
- avoid derays in the raarketing of products and reduce unneccessary
expendi ture,
- €ncourage research and production in the Community,s pharmaceutical
industry through the creation of an op€n market,
- consolidate the value on the internationar market of the quality
label attached to European nedicinal products;
considers, however, that discrimination shourd be used in extending
the range of tests conducted on rnedicinal products, however juEtifiable
in terrns of safety and efficacy, so as to avoid both unneceEsary
expenditure and excessive delays in the marketing of certain prod,ucts;
this applies particurarry to mutagenesis tests which are not yet
conpletely reliable;
considers also that the notes for guidance designed to assist the
harmonization of principres and methods for conducting tests should
be drawn up in such a way as to take into account both the requirernents
of pubJ-ic health and the constrai.nts involved in the research of any
nev, proprletary medicinal product, so as not to darnage Gapacity forinnovation in this sectori
stresses that the principle of mutual recognition of rnarketing
authorizatlons must not be undermined by the systenatic referial 0f
cases to t,he committee for proprietary lrledicinal products (cp!!p);
stres'es the importance in thiE connectlon of the rore assigned tothe CP&IP in the funplementation of this proeedure;
considers that the commission's propogars constitute a first step
toqrards the free movement of proprietary medicinar products in the
Community and that the creation of a climate of mutual trust is
essential for this procedure to be impremented and for further stepsto be taken;
ca1ls, thereforer upon the Commission and the Council
necessary Bteps to ensure that by I .Ian uary 19gg, the
the revision of the procedure, t,he mutual recognition
authorizations has become a matter of eoursei
approveB the Commission,s proposals.
to take the
date fixed for
of marketing
5.
6.
7.
8,
lnstructs its president to forvard this resolution
its committee to the Council and the Commission of
Communities.
and the report of
the European
9.
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BE:KPIATqI ORY STAITfEMENT
INTRODUCTION
1. One of the principal objectives of the Community is to ensure the
free movement of goods between the Meriber states. The i.rnplementation of
this principle in the field of medicinal products haE long been hampered
by the abusive use made by the tlember states of the exceptlons provlded
for in Article 36 of the EEC Treaty, relating to the protection of human
heatth and life.
In most caseg, ho*ever, reetrictions On the free movement of rnedicinal
products act against the real interests of the protection of h^alth - as
for example when the use of new and more effective remedies is needlessly
delayed in some t{ember states, ofr in the reverse case, when drugs whose
potentially harmful effects have been detacted in some l{anber States remain
in circuLation in others.
In general, the technical barriere to the free movement of proprietarT
medicinal products increase costs, slorr dorn the diffusion of medicinal
products and do not allow the consuner to benefit from the economies of
scale which production for the community market as a whola would permlt'
fn fact, research and
that Pharmaceutical firms,
are only able to meet them
devetoEnent costs in this sector are so high
particularly small and medLum-sized ones,
if they have a large market open to then'
2. To remedy this situation the commission is proposing a series of
amendments to the Directives already adopted aimed at supplementing the
harmonization meaEures already taken. Etrese new harmonization measures
must allor the mutual recognition of narketing authorizations and bring
about the genuine free movement of medicinal products, despite t'he
eontinued existence of other technical barriers'
The Commission's report on the approximation of legisl-ation relating
to proprietary medicinal products, the technical harmonization mo''sures and
the new marketing procedure will be examined in turn'
3. The cornmiesion's short report on the state of the European market for
medicinal products containe two sets of observations, the first relating to
the opening up of the market, the second to the insufficient transparency
of the market in this sector.
I.
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1. The deqree of openness of the narket
4- Four Council Directives and one Council Decision relating to the
abolition of barriers to the free movernent of medicinal products have so
far been adopted.l A..otding to the Connrission, these Directlves, which
concern more sPecifically safeguards for the develoFnent and manufacture
of mediclnal products, have been satisfactorily implemented in the Menber
States.
It has been possible to do away with systematic checks on imports
from one I'lember State to another, as the supervision of the develo;rnent
and manufaeture of medicinal products is carried out in accordance with
the same rules throughout the Community.
Marketing authorizations alone have remained a natlonal matter,
arthough cooperation bettveen competent authoritigs does take plaee
within the cornmittee for proprietary Medicinal products.
5- The Commission notes, howev.lr, that various inadequacies in Connrunity
legisrat,ion are hampering the free movement of medicinar products. rn
the main, these inadequacies are:
a) the lack of homogeneity in the Member States'regulations governing the
information reguired for the admission of new proprietary rnedl-cinaL
products to the market;
b) the inadequacies of the cpMp procedure 
- only eight applications for
marketing authorizations were filed under this procedure in four yearg.
The pharmaceutical industry would like to see the present procedure
repraced by a more effective system of mutual recognition.
1 Directi ve 65/G5/EEC of 26 January 1965Directive 75/3L8/EEC of 20 laay 1975Directive 75/3L9/Fac of 20 t4ay 1975Directive 78/25/EEC of L2 Oecernber 1977
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2. The other barriers to ttre free movernent
6. Although technical barriers are progressively disappoaring, other
types of barrier remain and these act indirectly against the free
movement of medicinal products. The fixing of pricee that are too Io\f,
for example, or the debarring of a medicine from reimburEement by
social security, conEtitute just as effective a barrier to free movernent
as the refusal of a marketing authorization. Such practiceE are l-n
violation of Article 30 of the EEC Treaty when their effect is to prevent
a producer or an import.er from selling his product on a EErtieular market.
Similarly, advertising malpractice can cauEe serious distortion of
competitl-on. In this field, horvever, the Commission considers that the
proposal for a Directive on mieleading and unfair advertiEingl provides
an adequate basis for consumer protection and that it would be inadvisable
to submit a specific proposal on proprietary medicinal products at the
present time.
FinalLy, the Commission ecncludes its report with a brief section
in which it stresses the primacy of research for the pharmaceutical
industry and underlines the potential importance at the level of
international trade of the quality labe1 attached to Community medicinal
products as a result of the harmonization of guarantees.
II.
7. To remedy the inadequacies of Community legislation as it norr Etands,
the Commission is proposing various amendments to Directives 65/65/REC'
7;/31B/EEC and 75/3LI/F.EC. The principal objective of these arnendments
le to increase the amount of information collected on medicinal products.
The Corunission is also submitting a proposal for a Council recommendation
aimed at harmonizLng the tests relating to the placing on the market of
proprietary medicinal Products-
1- Tncreased information
8. It is necessary in the interests of public health and the free
movement of products that the competent authorities, manufacturere and
consumers should have all relevant information readily at their disposal.
With this in view, all applicatlons for marketing authorlzations (new
Article 4a supplementing Article 4 of Directive 65/65/EEC) must henceforth
be accom[nnied by a data sheet containing information on the name,
pharmacological properties, clinical, pharmaceutical and adrainistrative
paiticulars of the product in question.
I bo.. coM(79) 353lfinal
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The data eheet may optionally be supplemented by economie particulars
(selling prlce to the public of the varioue sizee of packs, cost of dlaily
treatment, situation in respect of health insurance).
9. As far as the names of proprietary medicinal prod,ucts are concerned,
the amend,ment to Article 13, point I of Directive 55/65/EEC is essential.
The special name of a medicinal product must henceforth be follored ln
all cases by the international non-proprietary nErme, in legible charact-ers,
recommended by the world Health Organization. The purpose of this measure
is to facilitate the recognition of the real identity of products whlch
app€ar under a variety of special names, and Eo to ensure at least some
transparency in the market for medicinal products. l
The scientific information on proprietary rnedicinal prodr-rcts is alEo
to be supplemented by two new categories of test, in addLtion to those
described in the annex to DirectLve 75/3L8/EEC. lltrese additlonal tests
are for bioavailability (providing information on the rate at which and
in what proportions a medicine's active principle reachee the gite where
its action should oecur) and for mutagenesis (concernJ.ng changes ln the
genetic material which are spontaneous or caused by chemical products).
The study of bioavailability must be undErtaken in all cases where it le
eseential in the interests of the patient, that is where the therapeutlc
safety margin is narrow or where the previous testa have revealed anonaliee.
I0. The study of mutagenic potential is compulsory for all new sr.rbstanceE.
It would app€ar, however, that at the present level of scientific knopledge,
mutagenesis tests can produce a certain nurnber of 'fa1Ee positive'resultE.
This places a question rnark against the additional costs incurred and the
delays in making medicines which are safe and efficacious avallable to
patients, caused by the long term carcinogenicity tests which have to be
conducted when mutagenesis tests appear to be positive.
2. The harmonization of tests
11. In order to facilitate an identical interpretation of the Community
Directives when tests are carried out and when applications for marketing
authorizations are examined, the Commission is proposing, by neanE of a
Council Recommendation, that these tests should be conducted in aceordance
urith the common principles and methods set out in a series of notee for
guidance.
These notes for guidance, which have been drawn up by two groups of
scientific experts on 'safety and efficacy' within the cplr[.P, should nake
it possibl€ t,o avoid divergences between the Irlember States when conducting
the tests designed to verify the harmlessness, efficacy and quality of
T-
-The recent proposal from the Comoission for- a .Directiva relating .to para}Ielimports (Doc.24a/8O) is also aimed at preventing any modification of thegq3lfp!+Ye_gl_llgqp!+tlye_composition of proprietary products or their namesEor Purery commorcl-ar ends. - 
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medicinal prducts. These notes will inform applicants for marketing
authorizations in advance of the requirernent,s of the national authorities
and will spare them the need to repeat sirnilar tests.
L2. At the present time, the duplication of tests and the delays whlch
this entails combine to increase the coet of medicines and hamper the
frEe movement of products.
The notes for guidance will be revi6wed periodically to ensure that
they are continually adapted to scientific and technical progr€ss. AE
theEe scientific document,s must be interpreted in a flexible manner and
revised periodically, the Commiseion coneidered the Recommendation to be
the most appropriate instrument.
The representatives of the pharmaceutical industry consider that
these explanatory d,ocuments should not be d,rafted until the Commission
haE examined the need for them and the induEtry and the national
authorities have been properly consulted in advance. It would, be usefuJ-,
ln fact, if expertE frorn th,: raporatories of the pharmaceutical industry,
who are experienced in the praetical problems encountered in t.I.e initiation
of a research and development project in this field, could be involved
from the outset in the drawing up of the notes for guidance. The notes
for guidance should not be published until they have been unanimously
approved by the Committee for Proprietary Medicinal Products.
13. Furthermore, although the Recommendation is not binding upon the
lilember States (Art. 189 of the EEC Treaty), its terms must. be respected by
applieants for marketing authorizations, as it is the duty of the Member
States to ensure that tests are conducted in accordance wLth the method,s
set out in the notes for guidance. Iloqrever, if proper flexibility is
to be rnaintained in this matter, applicants who conduct equivalent teets
wlthout folloring the recommended rnethodology, but who can dernonEtrate that
they are at least as reliable, should be accepted.
III. THE NEW INARKETTNG PROCEDI'RE
1. The mutual fecoqnition of marketinq authorizations
L4. The procedure for marketing authorizations, as provided for in
Directive 75/3L9/EEC, has not been entirely satisfactory.
The conditionE for initiating the procedure have proved too
restrictive, particularly the requirernent that a request has to be made
for the product to be marketed in at least five lrlember States; it is aleo
reglettable that applicants do not have the opportunity to be heard during
the,procedure.
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All of those concerned, the pharmaeeutical industry no less than the
consumers' consultative corunittee, consider the present procedure to be
inappropriate. The Commission, hcwever, does not think lt advisable to
introduce a system of Community authorizations issued by a Europ€an agency.
The setting up of a European body with scientific exp€rts and the research
laboratories and administrative staff they would require would be
prohibitive in terms of cost, even without the political and legal problens
which a solution of this kind would involve.
15. The Commiesion proposes, therefore, to amend Chapter III of Directive
75/3L9/EEC relating to the Committee for Proprietary Medicinal Products.
Henceforth (Art. 9), the holder of a marketing authorLzation issued in
a Dlember State may request recognition of such authorization when he
files an application for authorization in one or more Member States.
This provision introduces the princlple of the mutual recognition
of marketing authorizations whieh Parliament has wiEhed to aee impleruented
for several ye"r".1
A number of objections have been raised to the mutual recognition of
marketing authorizations. Previously the national authoritiee refueed
to grant authorizations on the basis of the safeguard clauEe provided by
Article 36 of the EEC Treaty concerning prohibitions or restrictLone on
imports justified on grounds of the protection of health.
16. Hovrever, the Directives already adopted on this matter, together
with the supplementary inf,ormation and experimentation referred to above,
particularry the harmonl-zation of tests rerating to the pracing on the
market of medicinal products, are sufficient to ensure that any medicine
judged to be safe and efficacious in one Medber State is today able to
satisfy ipso facto the reguirements of another.
The introduction of this more rapid and more econonic procedure of
mutuar recognition is more likery, in fact, to be in the interests of
public health. Should a 'Iax' ltember State fail to comply with the
regulations or, on the contrary, impose more restrictive conditions than
those provLded for, then it would be the Comml-ssion's task to intervene and
put an end to these practices.
ID. K."r"maeker report, 
- 
Doc. 664/78
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2.
Recognition of marketing authorizations will be obtained within a
period of L2o days in the case of old products and 60 days in the case of
products containing a new substance' This shorter period can be
justifie(lbythefactthat,unlikeoldproducts,newproductshaVebeen
thesubjectofthoroughexperinentationinaccordancewithcontmon
principles which comply with the state of the art in science'
17. The role of the Committee for Proprietary Medicinal Products (CPMP) '
which consistE of representatives of the llember statee and of the commisELon'
is redefined. Henceforth, the committee will aseume a dual role' giving
opinionsandconsideringappeals.Ingenera},itEtaskwillbetoexamine,
at the request of its members, any question concerning the qual.Ly,
safet}andefficacyofaproprietarymedicinalproduct.Anational
authority will therefore be able to seek the opinion of th'e CPMP (Article 12)
before taking a decision on a pr:oblem of community interest' care must
be taken to see that the principLe of mutual recognition is not undermined
by the systematic referral of cases to the CPI4P'
trhe rolo assigned to the cpMp is i.mportant for the Proper implementatlon
oftheprocedure;asitisinformedofal-lapplicationsformarketing
authorization and of reasoned refusars to grant authorizatiorg, the
committee can be consulted when a national authority does not recognJ'ze
theauthorizationorwhennationaldecisionsclash(Article1l).
CONCLUSION
ls.flgosetsofconclusionsseemtoemergefromtheanalysisofthe
Commission' s ProPosals.
.Thereisnodoubtthattheproposalsthernselvesconstitutea
decisive step towards the harmonization of legislation in this field'
In fact, the implementation of provisions which ensure better lnformation
andgreatertransparencywithregardtoproprietarymedicinalproducte,
as well as the harmonization of tests, should enable the mutual recognLtion
of marketing authorizations to be attained'
Inthisrespect,t,hecreationofaclimateofmutualtru8tbettyeen
Member states is essential both for the procedure for mutual recognl-Etfr-'-
tobeimplementedandforfurtherstepstobetaken.ThecoEtrlissl.on
andtheCouncilshouldtakeallthenecegsaryBtepatoEtsurethatby
IJanuarylgEl,Lhedatefixedfortherevisionoftheprocedure,the
mutualrecognitionofmarketingauthorizationshasbecomeamatterof
course.
-13- pE 71.967/firL.
It ie essential that real freedom of rnovement of proprietary
medicinal products be achieved in the Community; the protection of
public health, the level of public health expenditure, the quality of
Comnunity production and the development of the pharmaceutLcal industry
all depend on it.
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